Jill Feldman: Must-read about the burdens and barriers patients face

Jill Feldman shared a post by Nathan Pennell, Vice Chair of Clinical Research at Cleveland Clinic Cancer Institute, on X:

“The burdens and barriers patients face when participating in dose-finding oncology trials (DFOTs) – This fantastic article focuses on the patient perspective.

There are direct AND indirect barriers BEYOND trial access and addressing these barriers will require partnering with patients! Tools such as PROMs should be used to understand the barriers/burden and to develop innovative solutions.

If you want to really understand the patient experience and/or take steps to improve it, this is a must-read!”

Quoting the post by Nathan Pennell:

“Amplifying the Patient’s Voice in Oncology Early-Phase Clinical Trials: Solutions to Burdens and Barriers | American Society of Clinical Oncology Educational Book.”

Authors: Kristen Spencer, Henry Butenschoen, Emily Alger, Melinda Bachini and Natalie Cook.

Source: Jill Feldman/X and Nathan Pennell/X

Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board.

Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.